ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Altimmune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.23+0.03 (+1.36%)
Close on Oct 19, 2026
- Market cap
- $413.54M
- P/E (TTM)
- –
- Dividend yield
- –
Altimmune statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Altimmune | Industry median |
|---|---|---|
| Market Cap | $433.77M | $164.85M |
| Enterprise Value | $142.24M | $87.06M |
| PB Ratio | 0.91 | 2.03 |
| P/TBV Ratio | 0.91 | 2.31 |
Income (trailing twelve months)
| Measure | Altimmune | Industry median |
|---|---|---|
| Operating Income | -$100.23M | -$21.44M |
| Pretax Income | -$91.76M | -$14.45M |
| Net Income | -$91.76M | -$22.46M |
| EBITDA | -$100.23M | -$16.91M |
| EPS (Diluted) | -$0.77 | -$0.83 |
Returns
| Measure | Altimmune | Industry median |
|---|---|---|
| Return on Equity (ROE) | -28.9% | -53.1% |
| Return on Assets (ROA) | -25.6% | -41.0% |
| Return on Invested Capital (ROIC) | -90.4% | -32.0% |
| Return on Capital Employed (ROCE) | -19.5% | -37.8% |
Growth
| Measure | Altimmune | Industry median |
|---|---|---|
| Revenue Growth (5Y CAGR) | -65.3% | 6.42% |
Balance sheet
| Measure | Altimmune | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $326.28M | $62.42M |
| Total Debt | $34.74M | $120.13M |
| Net Cash (Debt) | $291.54M | $15.68M |
| Net Cash Per Share | $1.50 | $0.66 |
| Equity (Book Value) | $474.21M | $48.79M |
| Book Value Per Share | $2.44 | $1.36 |
| Tangible Book Value | $474.21M | $23.06M |
| Working Capital | $322.31M | $75.77M |
Financial position
| Measure | Altimmune | Industry median |
|---|---|---|
| Current Ratio | 26.78 | 3.30 |
| Quick Ratio | 26.10 | 2.39 |
| Debt / Equity | 0.07 | 0.51 |
| Interest Coverage | -28.34 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Altimmune | Industry median |
|---|---|---|
| Operating Cash Flow | -$76.51M | -$12.35M |
| Capital Expenditures | -$54.00K | -$1.06M |
| Free Cash Flow | -$76.56M | -$20.28M |
| FCF Per Share | -$0.39 | -$0.42 |
Efficiency
| Measure | Altimmune | Industry median |
|---|---|---|
| Profits Per Employee | -$7.06M | -$703.34K |
| Employee Count | 13 | 74 |
Dividends and yields
| Measure | Altimmune | Industry median |
|---|---|---|
| Earnings Yield | -21.2% | -22.7% |
| FCF Yield | -17.7% | -9.07% |
| Buyback Yield | -25.4% | -0.73% |
| Shareholder Yield | -25.4% | 0.00% |
Shares
| Measure | Altimmune | Industry median |
|---|---|---|
| Shares Outstanding | 194,518,000 | 58,179,650 |
| Shares Change (YoY) | 68.8% | 11.1% |
| Shares Change (QoQ) | 49.3% | 0.54% |
| Float | 193,567,000 | 49,173,100 |
| Shares Held by Insiders | 0.49% | 11.6% |
| Shares Held by Institutions | 77.9% | 59.4% |
Scores
| Measure | Altimmune | Industry median |
|---|---|---|
| Altman Z-Score | 3.17 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Altimmune's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.